Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.59
-0.29 (-1.08%)
At close: Feb 11, 2026, 4:00 PM EST
26.05
-0.54 (-2.04%)
After-hours: Feb 11, 2026, 6:41 PM EST
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $99.22M in the quarter ending September 30, 2025, with 121.69% growth. This brings the company's revenue in the last twelve months to $317.93M, up 129.21% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$317.93M
Revenue Growth
+129.21%
P/S Ratio
10.57
Revenue / Employee
$929,617
Employees
342
Market Cap
3.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 909.05M |
| Catalyst Pharmaceuticals | 578.20M |
| Ligand Pharmaceuticals | 251.23M |
| Liquidia | 69.22M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
ARQT News
- 6 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis - GlobeNewsWire
- 16 days ago - Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa - GlobeNewsWire
- 20 days ago - Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - GlobeNewsWire
- 21 days ago - Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - GlobeNewsWire
- 4 weeks ago - Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 2 months ago - Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - GlobeNewsWire
- 2 months ago - Arcutis Biotherapeutics: The Earnings Inflection Has Arrived - Seeking Alpha